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ABSTRACT 
Persistent infection with human papillomavirus type 16 (HPV16) is the primary 
aetiological agent for cervical cancer. Viral particles initiate their life cycle by infecting 
basal keratinocytes of epithelium and amplifying their genome. Viral oncoproteins E6 
and E7 are responsible for causing host cells to proliferate, disrupting the regular 
differentiation regimen. Infections are typically cleared by a host immune response, but 
HPV16 is capable of persisting, increasing the chance of genomic integration and host 
cell transformation. It is thought that HPV16 can evade the innate immune response by 
down-regulating important molecules such as toll-like-receptors (TLRs): normally 
responsible for recognizing viral infection and activating immune-response genes by a 
signal transduction cascade. Epidemiological studies show natural E6 variants, Asian-
American (AA) and L83V, are found more often than the prototype in invasive cervical 
cancers. Increased oncogenic potential for AA and L83V E6 genes has been confirmed 
by recent studies, but the role of the viral life cycle remains uncertain for each variant. 
The effects of an active viral life cycle on innate immunity were tested by first 
establishing an organotypic tissue culture model for mimicking HPV-infected epithelium. 
This model was phenotypically verified by morphology and immunohistochemistry for 
HPV16 L2 capsid protein, proliferation marker BrdU, and differentiation markers K5 and 
K10. Expression analysis for viral and innate immune genes was performed using RT-
qPCR. Significantly, TLR3 and IFN-κ were down-regulated in AA and L83V variants 
compared to prototype HPV16, indicating a variant-specific viral life cycle effect on host 
innate immune defence. Future high-throughput analyses, such as microarray or RNA-
sequencing, can be used for global expression profiling. 
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LAY SUMMARY 
Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms. As we unravel the complexity of life we 
discover that disease occurs due to changes at the molecular level. The purpose of this 
research was to study the effect of human papillomavirus type 16 (HPV16), a cancer 
causing virus, on the natural immune defence of host cells. Previous studies show that 
genetic variations within the E6 gene of HPV16 are found more commonly in invasive 
cervical cancers. This fact raises the question: do these HPV16 E6 variants have an effect 
on our initial immune response, allowing infections to persist and lead to cancer? Since it 
is unethical to experiment on humans, it was necessary to establish life-like skin that can 
be grown in the lab to mimic the viral life cycle. My experiments verified that the life-
like skin was able to support viral growth and that key genes responsible for an initial 
immune response are negatively affected. Not only does this research extend the frontier 
of biological knowledge, but it also has important implications for our understanding, 
diagnosis, treatment, and prognosis of cancers caused by human papillomavirus type 16. 
 
 
 
iii 
 
DEDICATION 
To those who undertake the methodical pursuit of truth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
Professional 
 First and foremost I would like to thank Dr. Ingeborg Zehbe for her key role as 
my mentor and thesis supervisor. Thank you to my committee members, and earlier 
mentors, Dr. Lada Malek and Dr. Wensheng Qin for seeding my interest in research 
during my undergraduate years and continuing the support to this day. Additionally, 
thank you goes to Dr. Lynne Hampson as my external examiner in the subject of viral 
oncology. Finally, thank you to Eleanor Maunula for all her administrative work and 
patience. 
 I must also express my gratitude to the Lakehead University professors that 
allowed me to assist with their courses: Dr. Lada Malek for Cell Biology, Dr. David Law 
and Dr. Chris Phenix for Biochemistry I lab, and finally, Dr. Greg Pyle for Biostatistics. 
Additionally, thank you to all the undergraduate and graduate students I had the pleasure 
of working with; I'm sure I learned more from you than you did from me. 
 Thank you to all past and present Thunder Bay Regional Research Institute 
(TBRRI) students, scientists, and employees. You all provided an atmosphere of constant 
learning and collaboration. Thank you to Dr. David Law and fellow grad student Mike 
Broere for the use of your lab for Experion analysis of RNA. Thank you David Nurse of 
the Thunder Bay Regional Health Sciences Centre for your histological processing and 
discussions. Thank you to Dr. Paul Lambert and Denis Lee for their technical assistance 
and providing NIKS. Thank you Dr. Martin Müller for providing anti-HPV16 L2 
antibody.  
 
v 
 
Personal 
 Thankfully, I have the support of valued family, friends, comrades, and critters. 
I'm truly humbled by their collective intelligence, experience, compassion, and wit. I 
want to emphasize that these are the people that inspire me to push-on, and from which I 
build my character. Firstly, thank you to Miss Jessie Jones, for your loving support. You 
carried me, literally in some cases, through this time and for that I am truly grateful.  
 Thank you to my family, near and far, for your support throughout the years. I am 
forever appreciative of my father Arthur and mother Lina for their assistance and 
willingness to accept my life decisions. My younger sister Kate and brother Sterling, 
thanks for your understanding and time together. Thanks to Gram for her quick wit and 
unwavering support. Grazie Nono per l'ospitalità e esperienza di vita, però, mi dispiace 
informarvi che non sono ancora un dottore! Finally, thank you to Jackson cousin-brothers 
Ryan and Alex. Since childhood you've been pillars in my life; I don't see that ever 
changing. 
 I've been lucky enough to meet some exceptional people that I can fortunately say 
are friends. With over a decade of letting me be his sidekick, Mohammad Noroozi has 
been an amazing buddy. The biostats crew, consisting of Heidi Forsyth, Mike Broere, and 
Sarah Niccoli is another force to be reckoned with. Special thanks to Sarah, my lab-wife, 
for putting up with my pedantics (I think I just made up a word) and always being there 
to support me. NiccolJack sounds like a bad Canadian pop-rock group, but special 
extraordinary thanks for being my MSc war-buddy. Thanks to all the other students and 
lab members of TBRRI for the “out of the box” perspective and humour. 
vi 
 
TABLE OF CONTENTS  
 
ABSTRACT .........................................................................................................................i 
LAY SUMMARY .............................................................................................................. ii 
DEDICATION.................................................................................................................. iii 
ACKNOWLEDGEMENTS .............................................................................................iv 
LIST OF TABLES ............................................................................................................xi 
LIST OF FIGURES ........................................................................................................ xii 
LIST OF ABBREVIATIONS ....................................................................................... xiii 
1 INTRODUCTION........................................................................................................... 1 
1.1 Literature Review....................................................................................................... 1 
1.1.1 Tumour Viruses ................................................................................................. 1 
1.1.2 Normal Epithelium: Proliferation and Differentiation of Basal Keratinocytes . 1 
1.1.3 Human Papillomaviral Life Cycle ..................................................................... 2 
1.1.4 The Innate Immune System ............................................................................... 6 
1.1.5 Infectomics ......................................................................................................... 8 
1.2 Research Rationale..................................................................................................... 8 
1.3 Hypotheses ............................................................................................................... 11 
1.4 Research Aims ......................................................................................................... 11 
1.5 Method Development............................................................................................... 11 
vii 
 
2 MATERIALS AND METHODS ................................................................................. 12 
2.1 Cell Culture .............................................................................................................. 12 
2.1.1 Cell Lines and Routine Maintenance ............................................................... 12 
2.1.2 Cryogenic Storage of Cells .............................................................................. 14 
2.1.3 Thawing Cells .................................................................................................. 15 
2.1.4 Mycoplasma Testing and Treatment ................................................................ 16 
2.2 Establishment of Recombinant Viral Variant Constructs ........................................ 19 
2.3 Viral DNA Isolation and Preparation ...................................................................... 21 
2.3.1 Handling, Storage, Quantification, Purity, and Integrity of DNA ................... 21 
2.3.2 Bacterial Transformation and Purification of Plasmid DNA ........................... 21 
2.3.3 Restriction Enzyme Digestion ......................................................................... 25 
2.3.4 Agarose Gel Electrophoresis and Purification of DNA ................................... 25 
2.3.5 Ligation of Purified Viral DNA ....................................................................... 26 
2.4 Transfection of Viral DNA into an Immortalized Cell Line .................................... 26 
2.4.1 Preparation of Immortalized Keratinocytes ..................................................... 26 
2.4.2 Co-transfection Strategy .................................................................................. 27 
2.4.3 G418 Selection ................................................................................................. 27 
2.5 Characterization and Verification of Transfection Efficiency ................................. 28 
2.5.1 GFP Transfection Efficiency ........................................................................... 28 
viii 
 
2.5.2 Presence of Viral DNA .................................................................................... 28 
2.6 Establishment of Organotypic “3D Raft” Cultures .................................................. 29 
2.6.1 Preparation of the Dermal Equivalent .............................................................. 29 
2.6.2 Addition of Keratinocytes ................................................................................ 30 
2.6.3 Lifting Rafts for Stratification ......................................................................... 30 
2.7 Phenotypic Characterization of Rafts ...................................................................... 31 
2.7.1 Histological/Morphological Assessment of Harvested Rafts .......................... 31 
2.7.2 Immunohistochemistry: Viral Life Cycle, Proliferation, and Differentiation . 31 
2.8 RNA Expression Profiling ....................................................................................... 33 
2.8.1 Handling and Storage of RNA ......................................................................... 33 
2.8.2 RNA Extraction ............................................................................................... 33 
2.8.3 Quantification, Integrity, and Purity Assessment of RNA .............................. 33 
2.8.4 Reverse Transcription of RNA to cDNA ......................................................... 34 
2.8.5 Relative Expression by Real-Time Polymerase Chain Reaction ..................... 34 
2.8.6 Data Analyses and Statistics ............................................................................ 35 
3 RESULTS ...................................................................................................................... 36 
3.1 Establishment of Full-Length HPV16-Containing Keratinocytes ........................... 36 
3.1.1 Isolation of HPV16 DNA from Restriction Digested Plasmid ........................ 36 
3.1.2 GFP Transfection Efficiency ........................................................................... 38 
ix 
 
3.1.3 Presence of HPV16 E6 DNA ........................................................................... 38 
3.2 Development of Organotypic Tissue Culture Model ............................................... 38 
3.2.1 Elongation of dermal fibroblasts ...................................................................... 38 
3.3 Phenotypic Characterization of Organotypic Tissue Culture .................................. 41 
3.3.1 General Morphology ........................................................................................ 41 
3.3.2 Evidence of an Active Viral Life Cycle: HPV16 L2 Capsid Protein IHC ....... 41 
3.3.3 Proliferation Marker: BrdU IHC ...................................................................... 41 
3.3.4 Differentation Pattern: K5 and K10 IHC ......................................................... 45 
3.4 Viral Gene Expression Analysis by RT-qPCR ........................................................ 47 
3.4.1 HPV16 E6 ........................................................................................................ 47 
3.4.2 HPV16 E7 ........................................................................................................ 47 
3.4.3 HPV16 E1^E4 .................................................................................................. 47 
3.5 Innate Immune System Gene Expression Analysis by RT-qPCR ........................... 51 
3.5.1 Interferons ........................................................................................................ 51 
3.5.2 Toll-Like Receptors ......................................................................................... 53 
4 DISCUSSION ................................................................................................................ 55 
4.1 Establishment of HPV16 E6 Variant Cell Lines...................................................... 55 
4.2 Development of Organotypic Model ....................................................................... 56 
4.3 Phenotypic Characterization of Rafts ...................................................................... 57 
x 
 
4.4 Viral Gene Expression ............................................................................................. 59 
4.5 Innate Immune System Gene Expression ................................................................ 60 
5 CONCLUSIONS AND FUTURE DIRECTIONS ...................................................... 61 
6 REFERENCES .............................................................................................................. 63 
7 APPENDIX .................................................................................................................... 71 
7.1 Alternative Organotypic Culture Model .................................................................. 71 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF TABLES 
Table 1. Gene expression assays used for RT-qPCR (Applied Biosystems). ................... 35 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF FIGURES 
Figure 1. HPV-mediated progression to cervical cancer. ................................................... 3 
Figure 2. HPV16 genome and product roles. ...................................................................... 4 
Figure 3. Antiviral innate immune response. ...................................................................... 7 
Figure 4. Naturally occurring E6 oncoprotein variations…………………………….…..10 
Figure 5. J2/3T3 fibroblast nuclei stained with DAPI at 400X magnification. ................ 18 
Figure 6. Vector map of the 2686 base-pair (bp) empty pUC19 plasmid cloning vector 
(public domain). ................................................................................................................ 20 
Figure 7. Vector map of pReceiver-M03 plasmid cloning vector (GeneCopoeia). .......... 22 
Figure 8. Gel electrophoresis of BamHI digested plasmid DNA. .................................... 37 
Figure 9. Gel electrophoresis of HPV16 E6 DNA PCR products. ................................... 39 
Figure 10. Fibroblasts in dermal equivalent after 24 hours. ............................................. 40 
Figure 11. General morphology of raft cultures. .............................................................. 42 
Figure 12. Active viral life cycle: HPV16 L2 capsid protein. .......................................... 43 
Figure 13. Proliferation marker BrdU. .............................................................................. 44 
Figure 14. Differentiation markers K5/K10. ..................................................................... 46 
Figure 15. Relative expression of HPV16 E6 mRNA transcript. ..................................... 48 
Figure 16. Relative expression of HPV16 E7 mRNA transcript. ..................................... 49 
Figure 17. Relative expression of HPV16 E1^E4 mRNA transcript. ............................... 50 
Figure 18. Relative expression ratio of interferons. .......................................................... 52 
Figure 19. Relative expression ratio of toll-like receptors. ............................................... 54 
Figure 20. NIKS culture morphology with Alvetex® scaffold. ....................................... 72 
 
xiii 
 
LIST OF ABBREVIATIONS 
AA   Asian-American HPV16 E6 variant 
bp   Base-pair 
BrdU   Bromo-2-deoxyuridine 
cDNA   Complementary DNA 
CIN   Cervical Intraepithelial Neoplasia 
CO2   Carbon Dioxide 
Ct   Cycle threshold 
DAPI   4',6-diamidino-2-phenylindole 
dH2O   Distilled Water 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO   Dimethyl Sulfoxide 
DNA   Deoxyribonucleic Acid 
dsDNA  Double Stranded Deoxyribonucleic Acid 
DPBS   Dulbecco's Phosphate Buffered Saline 
EBV   Epstein-Barr Virus 
EDTA   Ethylenediaminetetraacetic Acid 
EGF   Epidermal Growth Factor 
FBS   Fetal Bovine Serum 
FFPE   Formalin-Fixed, Paraffin-Embedded 
GFP   Green Fluorescent Protein 
HBV   Hepatitis B Virus 
HPRT1  Hypoxanthine Phosphoribosyltransferase 1 
xiv 
 
HPV   Human Papillomavirus 
ICC   Immunocytochemistry 
IFN   Interferon 
IHC   Immunohistochemistry 
IL   Interleukin 
LB   Lysogeny Broth 
mAb   Monoclonal Antibody 
mRNA   Messenger RNA 
NIKS   Normal or Near-diploid Immortal Keratinocytes 
p53   Tumour Suppressor Protein 53 
PCR   Polymerase Chain Reaction 
pRb   Retinoblastoma Protein 
RNA   Ribonucleic Acid 
RQI   RNA Quality Indicator 
RT-qPCR  Reverse Transcription, Real-Time PCR 
SOC   Super Optimal Broth with Catabolite Repression 
TBE   Tris/Borate/EDTA 
TLR   Toll-Like Receptor 
UV   Ultraviolet 
 
 
 
 
 1 
 
1 INTRODUCTION 
1.1 Literature Review 
1.1.1 Tumour Viruses 
 Although evidence for an infectious aetiology of cancers had been discovered 
throughout the 20th century, it was not until the 70's and 80's that the concept began to 
take hold within the medical and scientific community (Zur Hausen, 2007). The steady 
advance of biotechnology saw a shift toward a molecular basis for disease, and with that, 
the acceptance that infectious agents, such as viruses, can be carcinogenic. Overall, it's 
thought that greater than 20% of cancers worldwide are due to infections (Zur Hausen, 
2007); prominent agents are Epstein-Barr virus (EBV), hepatitis B virus (HBV),  and 
human papillomavirus (HPV). My thesis concerns the role of this last agent, HPV; 
subsequent pages review our understanding of its life cycle and carcinogenic abilities. 
1.1.2 Normal Epithelium: Proliferation and Differentiation of Basal Keratinocytes 
 Human skin, or the integumentary system, is our first line of defence against the 
environment and infectious microorganisms (Miller and Harley, 2002). Skin consists of 
two main layers: epidermis and dermis. The dermis supports epidermal growth and 
contains fibroblasts, collagen fibre matrices, vessels, and glands. The epidermis consists 
of a stratified squamous epithelial layer: basal keratinocytes which proliferate and 
differentiate upward into flattened, keratinized cells at the surface (left-most part of 
Figure 1). 
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1.1.3 Human Papillomaviral Life Cycle 
 Human papillomaviruses (HPVs) are double-stranded DNA viruses that infect 
basal keratinocytes of skin and mucosa via micro-abrasions (zur Hausen, 2002). Infection 
with HPV is most common in the epithelia of the genital tract, resulting in benign ano-
genital warts. However, with persistent infection, integration of the HPV genome into 
host genomic DNA can cause low-grade ano-genital lesions (such as cervical intra-
epithelial neoplasia, CIN) progressing to invasive solid tumours of the cervix (Figure 1) 
(Woodman et al., 2007). HPVs are thus divided into two types based on their tumour-
forming potential: low-risk and high-risk (Stanley et al., 2007). HPV type 16, which is 
also an aetiological agent for some head and neck cancers (Dayyani et al., 2010), is the 
most prevalent of the high-risk types and therefore an important subject for study (zur 
Hausen, 1996).  
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Figure 1. HPV-mediated progression to cervical cancer. 
Viral particles infect basal keratinocytes through micro-abrasions. Expression of “early” 
viral genes allow episomal DNA replication. Following altered differentiation of 
keratinocytes, “late” expression enables viral DNA encapsidation and completion of the 
infectious viral life cycle. Infections may persist due to immune evasion causing genomic 
integration with potential progression to neoplasia or even invasive cancer (Woodman et 
al., 2007). 
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Figure 2. HPV16 genome and product roles. 
Drawing of the 8 kb HPV16 genome showing the regulatory region for viral gene 
expression, the eight genes, and the roles of each protein product (Cann, 2007). 
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 The complete HPV16 genome (Figure 2) is approximately 8 kb long and consists 
of a long control region (LCR/URR) for transcription of eight genes (six early expressed 
and two late expressed). The human papillomaviral life cycle begins when virus gains 
entry to basal keratinocytes followed by uncoating its protective capsid proteins 
(Doorbar, 2005). The viral genome is maintained episomally at a low-copy number, 
replicating along with the host DNA, aided by the E1 and possibly E2 proteins. Rather 
than following normal differentiation, infected cells continue to proliferate into the 
suprabasal layers due to E6 and E7 protein products disrupting cell cycle progression 
(Hamid et al., 2009): E6 disrupts tumour suppressor protein 53 (p53) and E7 disrupts 
retinoblastoma protein (pRb). Once in the upper layers of epithelium, the late promoter, 
residing in the E7 open reading frame, leads to an increase in E1, E2, E4, and E5, and 
ultimately viral genome amplification (Doorbar, 2005). A third late-gene product, the 
spliced transcript E1^E4, is present during early expression, but most abundant during the 
productive stage of a viral life cycle (Bodily et al., 2011). E1^E4 has been used as a 
marker for initiation of viral transcription and quantitatively as a measure of viral life 
cycle productivity. Once the viral genome has been amplified in the upper layers, E4 aids 
viral capsid synthesis with the activation of L1 and L2 proteins, encapsulating the viral 
DNA. Viral life cycle is completed when infectious virus is released back into the 
environment.  
 In cases of persistent host cell infection, viral DNA can integrate into the host 
genome, causing an interruption of the E2 gene (Stanley et al., 2007). Loss of E2 leads to 
uncontrolled expression of E6 and E7, eventually leading to uncontrolled proliferation 
and immortalization of host cells (Figure 1). The transformation mechanism of HPV16 
6 
 
E6 was unravelled following the discovery of its numerous cellular binding partners. The 
two zinc-binding domains and C-terminal PDZ-binding domain allow interaction with a 
variety of cellular proteins, with many that act at a transcriptional level (Mantovani and 
Banks, 2001; Kumar et al., 2002). Along with E6-associated protein (E6AP), HPV16 E6 
binds to and causes ubiquitinlyation and eventual proteosomal degradation of tumour 
suppressor protein p53 in vitro and in vivo (Lechner et al., 1992; Scheffner et al., 1992; 
Lagrange et al., 2005). Disruption of p53-mediated cellular response to DNA damage, 
which normally initiate the intrinsic apoptotic regimen of a cell, has also been 
demonstrated with E6 (Kessis et al., 1993). 
1.1.4 The Innate Immune System 
 The innate immune system, also called the nonspecific defence system, is 
responsible for first-line protection and raising the alarm (Wilson et al., 2011). Skin, as a 
physical barrier of differentiated keratinocytes, is the initial defence against invasion by 
microorganisms. However, when this barrier is breached, internal mechanisms of defense 
must be able to recognize pathogens and initiate an immune response. Trans-membrane 
receptor proteins, such as toll-like receptors (TLRs), are able to recognize foreign 
molecules and initiate a signal transduction cascade leading to immune-response gene 
expression (Wilson et al., 2011) (Figure 3). Viral recognition by TLRs results in 
downstream activation of important signalling molecules: interferons (IFNs) and 
inflammatory cytokines (Stanley et al., 2007). These are important for protecting the 
infected and surrounding cells as well as amplifying the immune response. Interestingly, 
there has been increasing evidence of a link between HPV immune evasion and 
oncogenicity (O'Brien and Campo, 2003). 
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Figure 3. Antiviral innate immune response.  
TLRs 1, 2, 4, and 6 can identify extracellular molecules and initiate a signal transduction 
cascade to activate inflammatory cytokines. TLRs 3, 7, 8, and 9 span endosomal 
membranes and can identify foreign molecules within cells, such as nucleic acids, 
initiating interferon and inflammatory cytokine activation (Boehme and Compton, 2004). 
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1.1.5 Infectomics 
 Broad gene expression changes, including those beyond the repression and 
induction of inflammatory molecules, can be studied using bioinformatics. This 
application of information technology to molecular biology, allows for system-wide 
analysis and understanding of biological systems. By obtaining global expression profiles 
of samples (via Affymetrix microarray or recently, RNA-sequencing) it's possible to 
identify patterns and networks of molecular interactions that are representative of an 
experimental manipulation. Infectomics is the systems biology study of infected host 
tissue; in other words, an infectome represents all the host molecular changes in response 
to a pathogen (Navratil et al., 2011). 
1.2 Research Rationale 
 Epidemiological studies have uncovered naturally-occurring HPV16 E6 
polymorphisms leading to variations in the amino acid sequence of the E6 oncoprotein 
(Zehbe et al., 1998). These variants are described based on their geographic distribution 
and origin of discovery: European prototype (first described), L83V, and Asian-American 
(AA, Q14H/H78Y/L83V). Amino acid sequence variations are identified in Figure 4. 
Most interestingly, these epidemiological studies indicate variant-specific prevalences in 
invasive cervical cancer due to suspected higher oncogenic potential of AA and L83V 
compared to prototype. Research has already been undertaken to determine the role of 
HPV16 E6 variants on oncogenic potential, mimicking a persistently infected and post-
integrated scenario (Zehbe et al., 2009). They differ in their ability to alter keratinocyte 
differentiation and p53 degradation (Stoppler, 1996). Additionally, recent studies on 
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primary human foreskin keratinocytes demonstrate in vitro transformation and increased 
migratory abilities by AA E6 alone (Richard et al., 2010; Niccoli et al., 2012). However, 
there is a significant knowledge gap; the full-length variant genomes have not been 
studied for initial effects in an early infection scenario. Taken with the fact that the 
majority of HPV infections are normally cleared, there is justification to consider that 
increased prevalence of HPV16 E6 variants in malignant tumours may be due to unique 
or augmented viral life cycle effects early-on within host cells. Given that HPV16 is 
known to evade viral recognition and response by modulating interferon and toll-like 
receptors (Stanley et al., 2007), the innate immune system is a good place to start looking 
for variant-specific effects before conducting costly high-throughput analyses. 
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Figure 4. Naturally occurring E6 oncoprotein variations. 
The amino acid sequence of prototype HPV16 E6 oncoprotein is 151 residues long from 
N-terminus to C-terminus. E6 has many cellular binding partners due to its two zinc-
binding domains. The L83V variant has a valine (Val, V) in place of a leucine (Leu, L) at 
the 83rd residue. The Asian-American variant (AA) has the L83V change in addition to a 
histidine (His, H) replacing glutamine (Gln, Q) at residue 14 and tyrosine (Tyr, Y) 
replacing histidine (His, H) at residue 78. 
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1.3 Hypotheses 
 Given epidemiological and laboratory findings, it's hypothesized the Asian-
American (AA) HPV16 E6 variant will be most successful in viral proliferation and host 
immune evasion. The null hypotheses are that there will be no differences in viral 
proliferation and host evasion between the variants. 
1.4 Research Aims 
1. Establish an organotypic raft infrastructure to facilitate the coincidence of 
HPV16 E6 variant life cycles with keratinocyte differentiation. 
2. Phenotypically characterize the organotypic cultures by morphological and 
immunohistochemical assessment. 
3. During the active viral life cycle, study molecular relationships of the innate 
immune system in the context of the variants; verify the model system for 
future high-throughput analyses. 
1.5 Method Development 
 As famously paraphrased from statistician George E. P. Box, "all models are 
wrong, but some are useful" (Box, 1976; Box et al., 1976). Although Box referred 
primarily to mathematical models, the concept can also be applied to experimental 
models. Manipulative experiments require a relevant model system for valid inferences, 
and in the case of this project, one that is capable of normal skin growth (differentiation 
regimen) and supporting an active viral life cycle. A review of human epidermis 
modelling highlights the history, variety, and use of organotypic tissues for research 
(Poumay and Coquette, 2007).  
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 Within the HPV research community, two prominent organotypic tissue culture 
doctrines have emerged: Lambertian and Meyersian. The Lambert lab developed a 
reliable culturing technique using normal immortalized keratinocytes (NIKS) capable of 
harbouring episomal viral copies and undergoing a full differentiation regimen (Flores et 
al., 1999; Flores et al., 2000; Genther et al., 2003; Lambert et al., 2005). To introduce 
full-length viral DNA into NIKS a chemical co-transfection strategy was employed in 
these studies. Meyers group, however, typically used a one-plasmid strategy with 
electroporation to introduce viral DNA (Yasumoto et al., 1986; McCance et al., 1988; 
Meyers et al., 2002). Due to established contacts and material availability the 
development of the model system employed herein was primarily influenced by Lambert 
lab methods. However, model optimization was required to establish a reliable procedure 
in our lab. 
 
2 MATERIALS AND METHODS 
2.1 Cell Culture 
2.1.1 Cell Lines and Routine Maintenance 
 Human cell cultures were maintained in a 37°C humidified incubator 
supplemented with 5% carbon dioxide (CO2) gas. Nutrient growth media was replaced 
every second day and cells were passaged (sub-cultured) at approximately 70% 
confluence. Sterile Dulbecco's phosphate buffered saline (DPBS; Invitrogen, Cat. No. 
14190) was used to remove any residual medium prior to cell detachment via 
trypsinization. Aseptic technique was strictly followed to maintain sterility and prevent 
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contamination. Cells were negative for Mycoplasma contamination as indicated by 
routine testing. 
Normal or near-diploid immortalized keratinocytes (NIKS), which are capable of 
a normal differentiation regimen and can maintain the HPV genome episomally, were 
grown on mitomycin-C-treated Swiss mouse J2/3T3 fibroblast feeder layers (Allen-
Hoffmann et al., 2000). Confluent J2/3T3 fibroblast cells, maintained normally in 
Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, Cat. No. D5796) 
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Cat. No. F6178) and 
1% antibiotic/antimycotic (Invitrogen, Cat. No. 15240-062), were reproductively 
inactivated by a two hour treatment with 4 µg/mL of mitomycin-C (Roche Canada, Cat. 
No. 107409). Inactivated feeders were sub-cultured at 10-20% density and incubated at 
least two hours and up to 48 hours before adding keratinocytes. NIKS were maintained in 
keratinocyte culture medium made up of 3 parts Ham’s F-12 medium (Invitrogen, Cat. 
No. 21700-075) supplemented with 7.5% sodium bicarbonate (Invitrogen, Cat. No. 
25080-094), 1 part DMEM (Sigma-Aldrich, Cat. No. D5796), 2.5% FBS (Sigma-Aldrich, 
Cat. No. F6178), 0.4 µg/mL hydrocortisone (Sigma-Aldrich, Cat. No. H4001), 8.4 ng/mL 
cholera toxin (Sigma-Aldrich, Cat. No. C8052), 5 µg/mL insulin (Sigma-Aldrich, Cat. 
No. I5500), 24 µg/mL adenine (Sigma-Aldrich, Cat. No. A2786), and 10 ng/mL 
epidermal growth factor (EGF; R&D Systems, Cat. No. 236-EG). NIKS were passaged 
between 1:5 and 1:10 with incomplete NIKS medium (without EGF) for the first 24 hours 
to allow stable growth, followed by a change to complete medium every other day for 
routine growth. When splitting NIKS, feeder cells were first removed by a short 
incubation with trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; Invitrogen, Cat. 
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No. 25300062) followed by vigrous washing with DPBS (Invitrogen, Cat. No. 14190). 
Feeder fibroblasts are less adherent and can be removed this way without disturbing the 
strongly adherent keratinocytes. NIKS transfected with full-length HPV16 DNA from 
three different E6 variants (prototype, L83V, and AA) were used as experimental 
treatments. NIKS containing the full-length episomal HPV16 genome (L83V variant, gift 
from Paul Lambert) were used as a positive control while untransfected NIKS were used 
as a negative control. 
 Primary human foreskin fibroblasts (ATCC CRL-2097) used for the dermal 
equivalent of organotypic raft cultures were only used at early-passage and maintained in 
human fibroblast medium: Ham’s F-12 medium (Invitrogen, Cat. No. 21700-075) or 
DMEM, supplemented with 10% FBS (Sigma-Aldrich, Cat. No. F6178) and 1% 
antibiotic/antimycotic (Invitrogen, Cat. No. 15240-062). 
Cervical carcinoma cell lines SiHa, CaSki, and C33A were all maintained in 
DMEM (Sigma-Aldrich, Cat. No. D5796) supplemented with 10% FBS (Sigma-Aldrich, 
Cat. No. F6178) and 1% antibiotic/antimycotic (Invitrogen, Cat. No. 15240-062). SiHa 
(ATCC HTB-35), which contains several integrated HPV16 copies per cell, was used as a 
positive control (Friedl et al., 1970). CaSki (ATCC CRL-1550), which contains about 
600 copies per cell of integrated HPV16 and some HPV16 sequences, was also used as a 
positive control (Pattillo et al., 1977). C33A (ATCC HTB-31), which is a HPV negative 
cervical carcinoma cell line, was used as a negative control (Auersperg, 1964).  
2.1.2 Cryogenic Storage of Cells 
 Confluent cells were prepared for cryogenic storage by aspirating growth medium 
followed by washing with sterile DPBS (Invitrogen, Cat. No. 14190) to remove any 
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residual medium. Cells were then lifted from the growth flask by incubating with trypsin-
EDTA (Invitrogen, Cat. No. 25300062) for 5 minutes at 37°C with 5% CO2. After 
confirming cells were lifted using an inverted microscope the trypsin-EDTA was 
inactivated by adding 9 parts growth medium. Total number of cells was determined by 
sampling 10 µL with a TC10™ Automated Cell Counter (Bio-Rad, Cat. No. 145-0009) or 
200 µL with a Coulter Particle Counter (Beckman Coulter Canada, Mississauga, ON). 
Unless otherwise desired, 1 x 10
6
 cells were centrifuged at 25 x g (Beckman GS-6KR 
Centrifuge) for five minutes, re-suspended in 900 µL of growth medium, and added to 1.5 
mL cryovials (Thermo Fisher Scientific, Cat. No. 66008-710) with 100 µL of the 
cryoprotectant dimethyl sulfoxide (DMSO; Sigma-Aldrich, Cat. No. 34869): 1 mL 
aliquots of 90% growth medium and 10% DMSO. Labelling conventions, e.g. “NIKS P3 
RJ 28 Dec 2010”, were consistently applied: cell identity, passage number, user, and date. 
Cryovials were placed in a controlled-rate cooling container (Thermo Fisher Scientific, 
Cat. No. 5100-0001), cooled to -80°C at 1°C/min, and subsequently transferred to liquid 
nitrogen for long-term cryogenic storage (Nunc Nalgene, 1998). 
2.1.3 Thawing Cells 
 Cryovials were safely removed from liquid nitrogen storage and immediately 
thawed to room temperature. Adhering to aseptic technique, the cryovial contents (1 mL) 
were transferred into a 15 mL conical tube containing 9 mL of the appropriate growth 
medium. Cryoprotectant (DMSO) was removed by centrifugation at 25 x g (Beckman GS-
6KR Centrifuge) for 5 minutes followed by aspiration of the supernatant. The cell pellet 
was re-suspended in growth medium, seeded into an appropriately sized growth vessel, 
and incubated at 37°C with 5% CO2 for normal growth. Alternatively, the thawed 
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cryovial contents were seeded directly into growth medium and vessel, effectively 
diluting the DMSO to non-toxic levels. Medium was changed the next day to ensure 
removal of any residual DMSO. 
2.1.4 Mycoplasma Testing and Treatment 
 Mycoplasma are a genus of prokaryotes that lack a cell wall, conferring resistance 
to common antibiotics, that are an insidious contaminant of mammalian cell culture. 
Contaminations can persist and cause metabolic stress, arginine depletion (Schimke et al., 
1966), poor transfection efficiencies (Xia et al., 1997), and gene expression changes 
(Jung et al., 2003) to host cultures; Mycoplasma can be quite problematic for 
experimental studies (Russell et al., 1975; Chen, 1977).  
 Due to the risk of contamination effects on experiments, cells were tested 
regularly for Mycoplasma contamination by fluorescent 4',6-diamidino-2-phenylindole 
(DAPI) staining. A strict regimen was established to track and limit the spread of 
Mycoplasma. Aseptic technique, along with thorough surface sterilization with 70% 
ethanol and ultraviolet (UV) radiation, was employed as a front-line defence. 
Furthermore, separation of culturing time, location, and reagents were maintained when 
handling potentially contaminated cultures (or those with unknown Mycoplasma history). 
All work with these "quarantine" cultures was delayed until after routine culturing to 
limit cross-contamination. Separate incubators and bio-safety cabinets were also used. As 
an additional precaution, reagents necessary for the maintenance of "quarantine" cultures 
were aliquoted for single-use to prevent contamination of working solutions.  
 Cultures were tested initially upon arrival, prior to making freeze-backs, and at 
least once a month during routine growth. Cells were grown at least one week in culture 
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after being established from cryogenic storage to allow detectable titres of contaminants 
to develop. Enough cells were seeded onto a sterilized glass cover slip (Thermo Fisher 
Scientific, Cat. No. 12-541A), placed in a 35 mm culture dish (VWR, Cat. No. CA25382-
064) by sterile forceps, to yield at least 50% confluency after 2-3 days. At which point, 
medium was removed from sub-confluent cells and replaced with a modified Carnoy's 
fixative (3 parts methanol (Thermo Fisher Scientific, Cat. No. A4544) to 1 part glacial 
acetic acid (Sigma-Aldrich, Cat. No. 695092-2.5L)) for 5 minutes. Fixative was removed 
and replaced with fresh fixative for an additional 10 minutes. Fixative was then removed 
and cover slips were allowed to air dry. The cover slips were mounted to a microscope 
slide using Vectashield mounting medium with DAPI (1.5 µg/mL, Vector Laboratories, 
Cat. No. H-1200) and allowed at least 5 minutes in the dark prior to fluorescent detection. 
Mounted slides were stored at 4°C in the dark if necessary. A fluorescence microscope 
with an excitation filter for 360 nm was used to visualize a 460 nm emission of blue-
fluorescing DNA. Mycoplasma were identified at 400X or 1000X (oil-immersion) 
magnification as small cocci or rods within or outside of a cell, distinct from cell nuclei 
(Figure 5). 
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Figure 5. J2/3T3 fibroblast nuclei stained with DAPI at 400X magnification. 
Adherent cells were cultured on cover glass in a 35 mm dish. Sub-confluent cells were 
fixed in Carnoy's fixative (3 parts methanol to 1 part glacial acetic acid), stained 
with DAPI, and mounted to a microscope slide. The 400X magnified image was captured 
using a Zeiss fluorescence microscope with 100 ms exposure for excitation/blue emission 
at 358/461 nm. The right image shows intracellular Mycoplasma contamination.  
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 The preferred response to Mycoplasma contamination was immediate bleach 
disinfection and disposal of the culture. When this was not possible, such as with 
precious cell lines, treatment was attempted. BM Cyclin (Roche Canada, Cat. No. 
10799050001), a set of drugs targeting bacterial ribosomal protein synthesis was used to 
treat Mycoplasma infected cultures (Fleckenstein and Drexler, 1996). Cells were treated 
for three weeks while alternating between BM Cyclin I and II, and grown for a final week 
in the absence of BM Cyclin before being screened. 
2.2 Establishment of Recombinant Viral Variant Constructs 
Recombinant DNA constructs of full-length HPV16 E6 variants were previously 
created by site-directed mutagenesis (Flores et al., 1999) and verified by DNA 
sequencing. Full-length viral DNA for each HPV16 E6 variant (Prototype, L83V, and 
AA) was cloned into the multiple cloning site of the high-copy number pUC19 (Figure 
6). 
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Figure 6. Vector map of the 2686 base-pair (bp) empty pUC19 plasmid cloning 
vector (public domain). 
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2.3 Viral DNA Isolation and Preparation 
2.3.1 Handling, Storage, Quantification, Purity, and Integrity of DNA 
 DNA was handled cautiously to avoid mechanical damage such as genomic 
shearing or plasmid nicking; vigorous pipetting and vortexing was explicitly avoided. 
DNA was stored in appropriate buffers (e.g., TRIS) and kept at 4°C for general short-
term storage. Plasmid DNA was kept at -20°C for long-term storage. Double-stranded 
DNA (dsDNA) samples were quantified using a Take3 micro-volume plate with a 
Synergy 4 spectrophotometer (BioTek, Winooski, VT). Sample volumes of 1 to 2 µL 
were measured and blanked with corresponding storage buffer. Absorbance was 
measured at wavelengths of 260 and 280 nm, yielding final concentration (ng/µL) and 
purity (A260/280). Pure nucleic acid samples, with low levels of detectable protein 
impurities, were indicated by A260/280 ≥ 1.8. Integrity of DNA was verified by agarose gel 
electrophoresis. Intact DNA had a discrete band of the appropriate size. 
2.3.2 Bacterial Transformation and Purification of Plasmid DNA 
 Plasmid cloning vectors were transformed into competent E. coli cells followed 
by kit-based plasmid purification. Viral constructs, containing full-length viral DNA 
within the multiple cloning site of the high-copy number pUC19 (Figure 6), conferred 
ampicillin resistance as a selective marker. Another type of ampicillin resistance-
conferring plasmid, pReceiver-MO3 (Figure 7), was used for its coding of green 
fluorescent protein (GFP) and neomycin resistance.   
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Figure 7. Vector map of pReceiver-M03 plasmid cloning vector (GeneCopoeia). 
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 First, selective agar plates were made by combining and stirring one LB 
(lysogeny broth) agar tablet (Sigma-Aldrich, Cat. No. L7025-500TAB) per 50 mL of 
distilled water (dH2O) in a 500 mL Erlenmeyer flask for two minutes. The flask was 
covered with aluminum foil and autoclaved on the liquid cycle to fully dissolve the 
tablets and sterilize the resulting solution. A 54°C water bath was used to cool the 
sterilized solution prior to the aseptic addition of ampicillin (Sigma-Aldrich, Cat. No. 
A9518-5G, stock 50 mg/mL) to a final concentration of 100 µg/mL. The LB agar plates 
were poured and allowed to dry in the tissue culture bio-safety cabinet. Extra plates were 
stored upside-down in a bag or saran wrap at 4°C.  
 Next, one vial of 5-alpha competent E. coli cells (New England BioLabs, Cat. No. 
C2992H), stored at -80°C, was thawed on ice for 10 minutes for each construct needed. 
At least 1 µL of desired plasmid DNA was added to the bacterial cell mixture followed 
by gentle mixing. The mixture was then placed on ice for 30 minutes, heat shocked in a 
42°C water bath for 30 seconds, and placed on ice for another 5 minutes. A volume of 
950 µL room temperature super optimal broth with catabolite repression (SOC, New 
England BioLabs) medium was added followed by 60 minutes of 37°C shaking at 250 
rpm (Barnstead International, Max
Q ™ Mini 4450). Whilst shaking, selective agar plates 
made previously were warmed to 37°C in the bacterial incubator. After shaking, cells 
were mixed thoroughly by flicking and inversion. Selective agar plates were spread with 
75 µL each and incubated overnight at 37°C in the bacterial incubator.  
 Broth was prepared as agar before, but rather with LB broth tablets (Sigma-
Aldrich, Cat. No. L7275-500TAB). The sterile solution was stored at room temperature 
and flame sterilized before and after each use. Aliquots of 5 mL LB broth in 15 mL 
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conical tubes were supplemented with 100 µg/mL of ampicillin. A single colony from 
each construct's plate was chosen, scooped using a sterile pipette tip, and placed into the 
5 mL of LB broth. Plates with remaining colonies were stored at 4°C and could be used 
for up to one month. Conical tube lids were slightly loosened before shaking at 37°C and 
300 rpm for 8 hours. 
 After the 8 hour growth and for each construct, 500 µL of cell suspension was 
added to 250 mL of LB broth with 100 µg/mL of ampicillin in a 1 L flask. These were 
covered with aluminum foil and placed in the shaker at 37°C and 300 rpm overnight. 
Additional 8 hour growth suspension was used to make glycerol stocks: 0.8 mL of cell 
suspension was added to 0.2 mL of 80% sterile glycerol (USB, Cat. No. US16374) in a 
cryovial (Thermo Fisher Scientific, Cat. No. 03-337-7Y). Glycerol stocks were stored at  
-80°C. When needed, a portion of frozen glycerol stock was scraped off and streaked 
onto an ampicillin-selective LB agar plate using a flame sterilized metal inoculating loop. 
The glycerol stock was returned to -80°C prior to thawing to prevent bacterial death. The 
streaked selective plate was incubated at 37°C overnight, followed by repetition of the 
same protocol. 
 After the final overnight growth, the cell suspension was aliquoted into 50 mL 
conical tubes (40 mL per tube). These were centrifuged at 6000 x g (Beckman Coulter 
Allegra™ 25R Centrifuge) for 15 minutes, followed by removal of supernatant by 
decanting, and purification of plasmid DNA using Qiagen's EndoFree Plasmid Maxi Kit 
(Qiagen, Cat. No. 12362). Bacterial cell pellets were stored at -20°C if not proceeding 
directly with purification. 
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2.3.3 Restriction Enzyme Digestion 
 Viral DNA was isolated from the pUC19 vector by first using a restriction 
endonuclease reaction. A total of 10 µg of each variant’s plasmid DNA was digested in 
four separate reactions (2.5 µg of DNA each) for 3 hours at 37°C using 10 U of buffered 
BamH1 enzyme (Thermo Fisher Scientific, Cat. No. ER0055). Reagents were combined 
in a microcentrifuge tube and made up to a 20 µL volume with nuclease-free water, 
incubated at 37°C for 3 hours, briefly centrifuged to prevent sample loss, and finally 
combined into a single tube of 80 µL per variant. Digested samples, containing the full-
length viral DNA and the linearized cut plasmid, were stored at 4°C if not proceeding 
directly with purification or -20°C for long-term storage. 
2.3.4 Agarose Gel Electrophoresis and Purification of DNA 
 Full-length viral DNA was isolated from the remaining plasmid DNA by gel 
electrophoresis followed by purification. A 0.8% agarose gel (PCR certified agarose; 
Bio-Rad, Cat. No. 161-3104) in Tris/Borate/EDTA (TBE) buffer including 0.5 µg/mL 
ethidium bromide (Invitrogen, Cat. No. 15585-011) was cast using a horizontal mini-gel 
apparatus and allowed to polymerize for 45 minutes with a 100 µL well-comb. Loading 
dye (6X, Fermentas, Cat. No. R0611) was added to restriction digested samples, 5 µL of 
GeneRuler™ 1 kb (Fermentas, Cat. No. SM0314) was used as a DNA ladder, while 
samples were split and loaded into two lanes to prevent spill over. Electrophoresis was 
run at 100 V for 2 hours to allow sufficient separation between empty plasmid DNA and 
full-length linearized HPV DNA.  
 Once the run was complete, a UV imager (BioSpectrum 410 Imaging System, 
UVP) was used with 365 nm transillumination and 0.1 seconds exposure to capture 
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images. The viral DNA was isolated from empty plasmid by excising the DNA bands 
from the agarose gel with a clean scalpel and use of a UV transillumination table. DNA 
pieces were cut out quickly to avoid UV damage and transferred to pre-weighed 
microcentrifuge tubes. Microcentrifuge tubes were re-weighed and gel purification was 
performed using Qiagen's QIAquick Gel Purification Kit (Qiagen, Cat. No. 28704). Each 
piece of agarose with DNA was purified and eluted with 30 µL. Purified DNA was 
quantified and tested for quality before proceeding to ligation.  
2.3.5 Ligation of Purified Viral DNA 
 Purified viral DNA was re-circularized as a full-length uninterrupted genome by 
performing ligation reactions. Each 20 µL ligation reaction was performed in a 0.2 mL 
tube with 1 µg of purified viral DNA, 2 µL T4 DNA ligase buffer (10X; Cedarlane, Cat. 
No. M0202S), and 1 µL of T4 DNA ligase enzyme (Cedarlane, Cat. No. M0202S). 
Nuclease-free dH2O was used if necessary to make up the reaction volume to 20 µL. 
Ligations were performed overnight at 16°C in a thermocycler (2720 Thermal Cycler, 
Applied Biosystems). Final prepared variant DNA was either used immediately for 
transfection or stored at 4°C. 
2.4 Transfection of Viral DNA into an Immortalized Cell Line 
2.4.1 Preparation of Immortalized Keratinocytes 
 NIKS were cultured as described earlier, trypsinized, and counted; 2.4 x 10
6
 cells 
total were required for duplicate transfections of 4 x 10
5
 cells/12.5 cm
2
 flask (VWR, Cat. 
No. CA29185-298). These cells were seeded out 24 hours prior to transfection. NIKS 
were seeded without feeders to increase transfection efficiency, but had to be maintained 
with low calcium NIKS medium and no EGF to prevent calcium-induced differentiation.  
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2.4.2 Co-transfection Strategy 
 Since the re-ligated full-length HPV16 variant genomes contain no selective 
marker a co-transfection strategy was employed. The full-length genomes were 
transfected into NIKS with an equal amount of plasmid containing genes for GFP and 
neomycin (G418) resistance. Under these conditions it is theoretically possible that four 
general cell populations would exist: NIKS with neither plasmid, NIKS with HPV16 but 
no GFP/neo plasmid, NIKS with GFP/neo but no HPV16, and NIKS with HPV16 and 
GFP/neo plasmid. Under selective conditions, we would expect about half of the 
remaining population to have HPV16 DNA. 
 FuGENE 6 Transfection Reagent (Roche Applied Science, Cat. No. 
11814443001) was used 3:1 to DNA (6 µL FuGENE reagent to 1 µg each of HPV16 and 
plasmid DNA). Cells were first washed with PBS and media was replaced with low 
calcium NIKS complete medium. The transfection reagent was incubated in 94 µL 
serum-free Ham's F12 for 5 minutes followed by 15 minutes with the DNA after flicking 
to mix. The transfection solution was added drop-wise and flasks were moved back and 
forth to evenly distribute the delivery. Cells were incubated at 37°C and 5% CO2 for 24 
hours. After 24 hours, transfected NIKS were split onto reproductively inactive feeder 
layers with regular NIKS incomplete medium (without EGF). These were incubated 
another 24 hours prior to selection. 
2.4.3 G418 Selection 
 To isolate colonies of successfully transfected NIKS, geneticin sulphate G418 
(neomycin; VWR, Cat. No. CA12001-688) was used as a selective agent over the course 
of 5 days. Day 1 of selection, beginning 48 hours after transfection and 24 hours after a 
28 
 
new feeder layer, saw the addition of 100 µg/mL of G418. On the second day fresh 
feeders were added to replace those killed by selection. Day 3 saw media changed with 
the addition of 50 µg/mL of G418. Feeders were again replaced on the fourth day. Day 5 
was the end of selection and media was not supplemented with G418 any longer. Fresh 
feeders were added again on day 6, followed by normal culturing of the cells. 
2.5 Characterization and Verification of Transfection Efficiency 
2.5.1 GFP Transfection Efficiency 
 Cells were observed under a fluorescent microscope 24 and 48 hours after 
transfection to verify transfection efficiency. For quantification of efficiency, 5 random 
fields of view were imaged in phase-contrast and fluorescence. The number of 
fluorescent cells in each was compared to the total number of cells, yielding percent 
transfection efficiency. However, given that GFP expression may be low and non-visible 
this indirect verification method was superseded by PCR detection of viral DNA. 
2.5.2 Presence of Viral DNA 
 DNA was extracted from early passage transfectants using the DNeasy Blood & 
Tissue Kit (Qiagen, Cat. No. 69504). Cells were harvested from culture as described 
previously, with a pellet of 5 x 10
5
 cells frozen and stored at -80°C until extraction. Kit 
instructions were followed, with duplicate 100 μL elutions performed for each sample. 
Extracted DNA was quantified as previously described. 
 Presence of viral DNA was assessed using DNA polymerase chain reaction (PCR) 
for HPV16 E6. PCR reactions were made up to 25 μL with nuclease-free dH2O and the 
following master mix components: 1X PCR Buffer, 1 mM MgCl2, 200 μM dNTPs, 0.5 
μM forward E6 primer (5'-CAATGTTTCAGGACCCACA-3'), 0.5 μM reverse E6 primer 
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(5'-GTTTCTCTACGTGTTCTTGA-3'), 2 U Taq Polymerase, and 100 ng template DNA. 
No-template controls were run with each reaction. Thermocycler (2720 Thermal Cycler, 
Applied Biosystems) parameters were as follows: 40 cycles of 1 min 94°C denaturation, 
1 min 60°C annealing, and 2 min 72°C extension. Final extension was performed for 7 
min at 72°C followed by a 4°C hold. Gel electrophoresis was performed as described 
previously to visualize the expected 448 bp amplicon. PCR products were loaded onto a 
1.5% agarose gel along with a 100 bp DNA ladder (New England BioLabs, Cat. No. 
N0467), and run for 1 hr at 100 V.  
2.6 Establishment of Organotypic “3D Raft” Cultures 
2.6.1 Preparation of the Dermal Equivalent 
 Early-passage human foreskin fibroblasts, cultured as described earlier, were 
trypsinized and counted; 1 x 10
6
 cells were resuspended in 2 mL of FBS (enough for 1 x 
10
5
 cells/dermal equivalent). A sterilized small glass beaker and magnetic stir-rod, 
contained on ice, atop a magnetic stirring plate, were used to mix the following 
components for 8-10 equivalents whilst avoiding bubbles: 7.5 mL undiluted rat tail 
collagen type I (3.75 – 4.00 mg/mL; Millipore, Cat. No. 08-115), 1 mL Hanks’ Balanced 
Salt solution (10X, Modified, without calcium, magnesium or sodium bicarbonate; 
Sigma-Aldrich, Cat. No. H4385), 30 µL of 5 N sodium hydroxide to neutralize the 
collagen and initiate gel solidification, and 2 mL of thoroughly resuspended fibroblasts (1 
x 10
6
 cells). The stirring speed was slightly increased and 1 mL of dermal equivalent mix 
was quickly and carefully pipetted into each of 8-10 wells in a 24 well plate. Some loss 
was expected due to excess bubbles and viscosity. Dermal equivalents were incubated for 
20 minutes at 37°C and 5% CO2 to allow solidification (verified by opaque appearance 
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and inversion test). This process was repeated as necessary depending on the required 
number of cultures; typically, three preparations were performed consecutively to yield a 
minimum of 24 dermal equivalents. Finally, 1 mL of fibroblast growth medium was 
added to each dermal equivalent well followed by overnight incubation at 37°C and 5% 
CO2. Next day, homogenous distribution and elongation of fibroblasts was confirmed 
before proceeding. 
2.6.2 Addition of Keratinocytes 
 Normal immortalized keratinocytes (NIKS), cultured as described earlier, were 
trypsinized and counted; 3 x 10
6
 cells were thoroughly resuspended in 1 mL NIKS 
complete medium (enough for 6 rafts; 5 x 10
5
/raft). Fibroblast medium was carefully 
removed from the dermal equivalents and 100 µL of keratinocytes were added to each 
well. After evenly distributing the cells across the dermal equivalent the keratinocytes 
were allowed to attach for 2 hours at 37°C and 5% CO2. This process was repeated for 
each NIKS variant. Following this incubation period 1 mL of NIKS complete medium 
was added to each well. Rafts were once again incubated overnight at 37°C and 5% CO2. 
Next day, homogenously distributed and 100% confluent keratinocytes were confirmed 
before proceeding. 
2.6.3 Lifting Rafts for Stratification 
 NIKS medium was carefully removed from the rafts without puncturing the gel. 
Prior to lifting the rafts to the air-liquid interface, sterile cell culture inserts (30 mm, 
hydrophilic PTFE membrane, 0.4 µm; Millipore, Cat. No. PICM0RG50) were inserted 
into 6-well plates along with the addition of 1.1 mL of FAD medium (NIKS medium 
without EGF and with 1.88 mM Ca
2+
) to the bottom. Rafts were then lifted onto the 
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membranes using a Pasteur pipette to loosen and a sterilized scoop to transfer the gels. 
Any fluid that formed on top of the membrane was removed so that the cells may only be 
fed through the bottom of the membrane. To allow epithelial stratification and viral life 
cycle , rafts were incubated at 37°C and 5% CO2 for 14 days, changing media every 
second day. For a batch of 6 rafts, half were randomly designated for histological 
processing and half for RNA extraction. On day 14, rafts destined for histology were 
supplemented with 1.1 mL FAD medium containing 10 μM of thymidine analog bromo-
2-deoxyuridine (BrdU) for 24 hours. 
2.7 Phenotypic Characterization of Rafts 
2.7.1 Histological/Morphological Assessment of Harvested Rafts 
 Half the rafts were harvested on day 15 for histological analysis by first washing 
away any residual media with PBS. Rafts were fixed by submersion in 10% formalin for 
24 hours at room temperature. After formalin-fixation the rafts were washed and 
submerged in 70% ethanol. The histology lab of the Thunder Bay Regional Health 
Sciences Centre processed the tissue by bisecting, embedding in paraffin wax, sectioning 
by microtome (4 µm thickness), and mounting on positively-charged microscope slides. 
One pair of sections from each raft was haematoxylin and eosin stained for visualization 
of histological features. The remaining sections were provided unstained. 
2.7.2 Immunohistochemistry: Viral Life Cycle, Proliferation, and Differentiation 
 Phenotypic characterization included confirming presence and localization of 
HPV16 L2 capsid protein for active viral life cycle, BrdU for proliferation, and K5/K10 
for differentiation. Formalin-fixed, paraffin-embedded (FFPE) tissue slides were prepared 
by oven-baking at 60°C for 1 hour or alternatively, 37°C overnight. Paraffin was 
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removed by a series of triplicate 100% xylenes (Fisher Scientific, Cat. No. X3S-4) 
washes followed by triplicate 100% ethanol washes. Antigen retrieval was performed 
with 0.01 M citrate buffer and a pressure cooker (Pascal, Dako Cytomation) at 125°C and 
20 psi. Monoclonal mouse primary antibodies for HPV16 L2 (Gift from Dr. Martin 
Müller, #4D11), BrdU (Invitrogen, Cat. No. ZBU30), and K10 (DAKO, Cat. No. M7002) 
were diluted 1:100 in background reducing diluent (Dako, Cat. No. S3022) and applied 
overnight at 4°C in a dark humidified chamber. Double-staining for K5 (together with 
K10) was done with rabbit polyclonal antibody K5 (Abcam, Cat. No. ab24647-50) 
diluted 1:10,000. As a negative technical control, diluent was used. Unbound primary 
antibody was removed by triplicate 10 min PBS washes. For HPV16 L2, BrdU, and K10, 
donkey anti-mouse secondary antibody-conjugated to Alexa Fluor® 594 (1:800, Life 
Technologies, Cat. No. A-21203) was applied for 30 min at room temperature in a dark 
humidified chamber. For K5, donkey anti-rabbit secondary antibody-conjugated to Alexa 
Fluor® 488 (1:400, Life Technologies, Cat. No. A-21206) was used. Unbound secondary 
antibody was removed by triplicate 10 min PBS washes followed by triplicate dH2O 
washes. Slides were mounted using Vectashield with DAPI (1.5 µg/mL, Vector 
Laboratories, Cat. No. H-1200) and stored in a light-protected slide organizer.  
 Fluorescence was visualized and digitally captured using an inverted fluorescent 
microscope (Zeiss Axiovert 200 with mbq 52 ac power supply), digital camera 
attachment (QImaging QICAM Q21310), and Northern Eclipse software. For 350 nm 
emission (blue), 100 ms exposure time was used. For 488 nm (green) and 594 nm (red), 
2.5 or 5.0 s exposure time was used. Images were captured with 1x1 binning, 1280x1024 
resolution, 2.26% gain, 50.01% offset, and saved as ".bmp". Post-capture modifications 
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(such as overlays) were performed using ImageJ (version 1.47a, Schneider et al., 2012) 
and applied consistently to all image sets. Background fluorescence was subtracted by 
digital thresholding followed by linear adjustments to brightness and contrast. 
2.8 RNA Expression Profiling 
2.8.1 Handling and Storage of RNA 
 All RNA samples were stored at -80°C and only handled after using RNase-
removing sprays on gloved hands and work surfaces. Sterile nuclease-free dH2O was 
used for dilutions, nuclease-free plasticware, filter tips, and independent micropipettors 
were used for all pipetting. 
2.8.2 RNA Extraction 
 Half the rafts were harvested for RNA extraction by first washing away residual 
medium with PBS. Sterile forceps were used to detach the epithelium and dermis into 
separate pre-labelled sterile nuclease-free 2 mL cryovials. Harvested samples were 
immediately flash-frozen using liquid nitrogen and stored at -80°C. RNA was extracted 
using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Cat. No. KIT0204), 
with the optional DNase treatment, and eluted in 30 µL of provided elution buffer. 
2.8.3 Quantification, Integrity, and Purity Assessment of RNA 
 RNA quantity (in ng/µL) and integrity (28S:18S) was assessed using the Bio-Rad 
Experion Automated Electrophoresis system with a StdSens Analysis microfluidics kit 
(Bio-Rad, Cat. No. 700-7111).  RNA quality indicator (RQI) values above 7.0 were 
considered representative of non-degraded RNA. A Take3 micro-volume plate with a 
Synergy 4 spectrophotometer (BioTek, Winooski, VT) was used to assess RNA purity 
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(A260/280). Pure nucleic acid samples, with low levels of detectable protein impurities, 
were indicated by A260/280 ≥ 1.9. RNA samples were diluted to 100 ng/µL. 
2.8.4 Reverse Transcription of RNA to cDNA 
 Prior to Reverse Transcription Real-Time PCR (RT-qPCR), RNA was reverse 
transcribed to complementary DNA (cDNA) using the High Capacity cDNA Archive Kit 
(Applied Biosystems, Cat. No. 4322171). Reactions were made up to 60 μL with the 
following master mix components: 1X RT buffer, 1X primers, 1X dNTPs, multiscribe 
enzyme, nuclease-free dH2O, and 30 μL RNA template. No-template controls were run 
with each reaction. Thermocycler (2720 Thermal Cycler, Applied Biosystems) 
parameters were as follows: 10 min 25°C, 120 min 37°C, and 5 min 85°C followed by a 
4°C hold. 
2.8.5 Relative Expression by Real-Time Polymerase Chain Reaction 
 Viral mRNA transcript expression, along with others of interest, was analyzed by 
RT-qPCR with the Applied Biosystems 7500 Real-Time PCR System. Reactions 
consisted of 150 ng of cDNA, 45 μL of TaqMan® Gene Expression Master Mix (Applied 
Biosystems, Cat. No. 4369016), 4.5 μL of TaqMan® Gene Expression Assay hydrolysis 
probes (Table 1), and nuclease-free dH2O to make up volume to 90 μL. Triplicate 
reaction volumes of 25 μL were loaded into a transparent 96-well plate and analyzed. To 
assess inter-plate variability, a positive tumour control along with negative control of 
nuclease-free dH2O was run on each plate with the reference gene hypoxanthine 
phosphoribosyltransferase 1 (HPRT1). HPRT1 was chosen as a suitable reference gene 
based on previous optimization experiments (DeCarlo et al., 2008). 
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Table 1. Gene expression assays used for RT-qPCR (Applied Biosystems). 
TaqMan® Gene Expression Assay Assay ID 
HPRT1 Hs99999909_m1 
*HPV16 E6 AIAAY0O 
*HPV16 E7 AIBJW6W 
*HPV16 E1^E4 AIT9552 
TLR3 Hs00152933_m1 
TLR4 Hs00152937_m1 
TLR7 Hs00152971_m1 
TLR8 Hs00152972_m1 
TLR9 Hs00152973_m1 
IFN-β Hs00277188_s1 
IFN-γ Hs00174143_m1 
IFN-κ Hs00737883_m1 
IFN-λ (IL-29) Hs00601677_g1 
* denotes custom-designed assay 
 
2.8.6 Data Analyses and Statistics 
 Cycle threshold (Ct) data was exported as comma-separated value (".csv") files, 
and organized for analysis in Microsoft Office Excel 2007. For viral gene expression, 
since the control sample has zero expression, relative expression was calculated by the 
modified Livak method (2
(Ct(ref) - Ct(target)
). For non-viral gene expression, where the use of 
a calibrator sample was possible, relative expression ratio was calculated by the Livak 
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method (2
-ΔΔCt
, Livak and Schmittgen, 2001). Both methods assume amplification 
efficiencies of the reference and target gene similarly close to 100%: E = 2.  
 All statistical analysis and subsequent figure creation was performed using the 
statistical programming language R (version 2.15.0; R Development Core Team, 2010). 
Significance level (α) was set, a priori, at 0.05. Data was determined to meet parametric 
assumptions based on normality, homogeneity of variance, and independence. Normality 
was tested using histogram, Q-Q plots, and Shapiro-Wilk's test. Homogeneity of variance 
was tested using a Bartlett or Levene test. If parametric assumptions were met, an 
ANOVA was employed with Tukey's HSD post-hoc if appropriate. Non-parametric data 
was either transformed to reclaim parametric assumptions, or subjected to the non-
parametric Kruskal-Wallis test followed by Nemenyi or pair-wise Wilcoxon rank-sum 
post-hoc. Unless otherwise indicated, data are presented as means +/- SEM. 
 
3 RESULTS 
3.1 Establishment of Full-Length HPV16-Containing Keratinocytes 
3.1.1 Isolation of HPV16 DNA from Restriction Digested Plasmid 
 Restriction endonuclease BamHI was successfully used to cut the full-length 
HPV16 genomes from their 2.7 kb plasmids (Figure 8). All three E6 variants had similar 
yield of viral DNA. 
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Figure 8. Gel electrophoresis of BamHI digested plasmid DNA. 
A 0.8% agarose gel was used to separate restriction digested HPV DNA from its vector. 
Before and after gel excision of 8 kb-sized viral genome is shown; the remaining pUC19 
plasmid at 2.7 kb is seen below. Lanes 1-2: Prototype; Lanes 3-4: AA; Lanes 5-6: L83V. 
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3.1.2 GFP Transfection Efficiency 
 Fluorescent detection of GFP positive cells was an indirect and poor indicator of 
transfection success. Typically, after 24 and 48 hours, 10-30% of cells were GFP 
positive. However, GFP expression dropped off and was not evident during or after 
selection. A more reliable transfection validation technique was used. 
3.1.3 Presence of HPV16 E6 DNA 
 DNA PCR for HPV16 E6 was performed for direct evidence of transfection 
success (Figure 9). All three HPV16 E6 variants that were co-transfected had E6 
amplicons of expected size and similar intensity. Untransfected NIKS was used as a 
negative control. 
3.2 Development of Organotypic Tissue Culture Model 
3.2.1 Elongation of dermal fibroblasts 
 A major checkpoint in the development of organotypic tissue cultures was 
verification of the dermal equivalents. Rafts were checked 24 hours after preparing the 
collagen matrix with embedded dermal fibroblasts for two key characteristics: 
homogenous distribution of fibroblasts throughout the dermis and elongation. Rafts were 
only continued if these criteria were met (Figure 10). 
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Figure 9. Gel electrophoresis of HPV16 E6 DNA PCR products. 
A 1.5% agarose gel was used to assess E6 PCR products (448 bp amplicon). Lane 1: 100 
bp DNA ladder; Lane 2: NIKS only; Lanes 3-5: NIKS16+ Proto, L83V, and AA. 
 
 
 
 
40 
 
 
 
 
 
 
Figure 10. Fibroblasts in dermal equivalent after 24 hours. 
Phase-contrast images of homogenously distributed and elongated fibroblasts embedded 
within the dermal equivalent of organotypic tissue culture: (A) 25X magnification shows 
homogenous distribution and (B) 400X magnification shows elongation of individual 
fibroblast.  
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3.3 Phenotypic Characterization of Organotypic Tissue Culture 
3.3.1 General Morphology 
 Rafts had fully differentiated epithelium on the distal perimeter of each circular 
culture (Figure 11). The medial areas were thinner in comparison (only a monolayer of 
cells in some cases). Overall, untransfected NIKS epithelium appeared to be the thinnest 
while the three variants had thicker layers. In some cases there are obvious 
squamous/keratinized cells (corresponding to stratum granulosum and perhaps lucidum) 
in uppermost layers. In prototype and L83V cultures, some keratinized areas were seen in 
middle layers. 
3.3.2 Evidence of an Active Viral Life Cycle: HPV16 L2 Capsid Protein IHC 
 HPV16 L2 capsid protein was used as a marker for the viral life cycle, observed 
in the upper layers. L2 staining was seen in all variant replicates, in upper layers, but not 
consistently across entire sections (Figure 12). No specific L2 staining was seen in 
untransfected NIKS. There appeared to be less capsid protein in AA compared to Proto 
and L83V. The squamous layer of some sections separated, likely due to processing. 
3.3.3 Proliferation Marker: BrdU IHC 
 BrdU was added to culture medium 24 hours before harvesting. HPV16-
containing rafts are known to have suprabasal proliferation and therefore would contain 
BrdU-positive suprabasal cells (Flores et al., 1999). In untransfected NIKS, only basal 
cells had BrdU incorporation (Figure 13). In Proto and L83V there was some suprabasal 
incorporation. In AA almost all suprabasal cells had some BrdU incorporation. 
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Figure 11. General morphology of raft cultures. 
Haematoxylin and eosin stain of sectioned formalin-fixed paraffin-embedded raft cultures 
(200X magnification, biological triplicates). A differentiated epidermal layer is seen 
above the dermal equivalent collagen with fibroblasts. Below, the skin layers are labelled 
in an enlarged representative image. 
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Figure 12. Active viral life cycle: HPV16 L2 capsid protein. 
Fluorescent micrograph of sectioned formalin-fixed paraffin-embedded raft cultures 
(400X magnification, biological triplicates). Red fluorescence represents HPV16 L2 in 
the superficial zone of epithelium. Blue fluorescence represents nuclear-staining by 
DAPI. In rare cases (as in prototype #1), DAPI staining was inconsistent throughout the 
entire epithelium. Below, a labelled representative image is shown. 
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Figure 13. Proliferation marker BrdU. 
Fluorescent micrograph of sectioned formalin-fixed paraffin-embedded raft cultures 
(200X magnification, biological triplicates). Red fluorescence represents proliferation 
marker BrdU, incorporated into nuclei of active cells. Minor background auto-
fluorescence is apparent on section edges. Below, a labelled representative image is 
shown. 
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3.3.4 Differentation Pattern: K5 and K10 IHC 
 Keratin 5 was used as a basal cell differentiation marker while keratin 10 was 
used for suprabasal cell differentiation, based on previous reports (Zehbe et al., 2009). 
HPV16-containing rafts would likely have differential staining patterns: K5 suprabasal 
and K10 disrupted. In untransfected NIKS there was basal K5 staining with thick 
suprabasal K10 (Figure 14). In the variants, K5 staining was not isolated to the basal 
layer. In some areas of the variant epithelia K5 can be seen invading into the superficial 
zone and squamous layer. K10 is seen in the suprabasal and squamous layers for all rafts, 
but there are some areas of the variants where staining is disrupted and diminished. 
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Figure 14. Differentiation markers K5/K10. 
Fluorescent micrograph of sectioned formalin-fixed paraffin-embedded raft cultures 
(200X magnification, biological triplicates). Green fluorescence represents basal 
keratinocyte marker K5 while red represents suprabasal cell marker K10. Below, a 
labelled representative image is shown. 
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3.4 Viral Gene Expression Analysis by RT-qPCR 
 Viral mRNA transcript expression was measured from organotypic raft cultures 
grown for two weeks. Custom assays were designed and used in RT-qPCR reactions to 
relatively quantify the expression of HPV16 E6, E7, and E1^E4. E6 and E7 are the two 
prominent oncogenes while E1^E4 is suspected to be a marker of productive viral life 
cycle.  
3.4.1 HPV16 E6 
 During a typical viral life cycle oncogene E6 expression is kept low by its 
modulator, E2 (Woodman et al., 2007). In our experiments, E6 expression was detected 
in all variants (Ct = 23 to 29) and not detected in the untransfected control (Ct = 40) 
(Figure 15). Relative expression of E6, in reference to stable HPRT1 expression, was not 
significantly different between variants (P > 0.17). 
3.4.2 HPV16 E7 
 As with E6, oncogene E7 expression remains low during the viral life cycle 
(Woodman et al., 2007). In our experiments, E7 expression followed a similar pattern as 
E6, with no significant differences between variants (Ct = 20 to 26, P > 0.17) (Figure 
16).  
3.4.3 HPV16 E1^E4 
 The spliced transcript E1^E4 is used as a late viral life cycle marker (Bodily et al., 
2011). In our experiments, E1^E4 was not detected in the untransfected control while 
expression was not significantly different between variants (Ct = 25 to 38, P > 0.17) 
(Figure 17). AA had extremely low but detectable E1^E4 expression (Ct ~38). 
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Figure 15. Relative expression of HPV16 E6 mRNA transcript. 
Relative expression was calculated by the modified Livak method (2 ^ delta Ct) because 
the control/calibrator sample has zero viral gene expression. HPRT1 was used a reference 
gene. Although AA was significantly higher than NIKS (P < 0.05), E6 expression was 
not significantly different among variants (P > 0.17). Data are presented as mean +/- 
SEM (n = 3) while statistical analyses were performed by Krusk-Wallis rank sum test 
followed by Nemenyi post-hoc tests. 
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Figure 16. Relative expression of HPV16 E7 mRNA transcript. 
Relative expression was calculated by the modified Livak method (2 ^ delta Ct) because 
the control/calibrator sample has zero viral gene expression. HPRT1 was used a reference 
gene. AA was significantly higher than NIKS (P < 0.05) while E7 expression was not 
significantly different among variants (P > 0.17). Data are presented as mean +/- SEM (n 
= 3) while statistical analyses were performed by Krusk-Wallis rank sum test followed by 
Nemenyi post-hoc tests. 
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Figure 17. Relative expression of HPV16 E1^E4 mRNA transcript. 
Relative expression was calculated by the modified Livak method (2 ^ delta Ct) because 
the control/calibrator sample has zero viral gene expression. HPRT1 was used a reference 
gene. Prototype was significantly higher than NIKS (P < 0.05) while E1^E4 expression 
was not significantly different among variants (P > 0.17). Although apparently zero, AA 
had low but detectable E1^E4 expression. Data are presented as mean +/- SEM (n = 3) 
while statistical analyses were performed by Krusk-Wallis rank sum test followed by 
Nemenyi post-hoc tests. 
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3.5 Innate Immune System Gene Expression Analysis by RT-qPCR 
 Variant-specific changes to interferon and TLR mRNA transcript expression were 
analyzed due to their importance in the host innate immune response.  
3.5.1 Interferons 
 Interferon expression was low, evidenced by high Ct values. As a result, 
interpretations should be cautious. IFN beta had higher expression (Ct = 30 to 37), but 
with noticeable biological variability (but very low technical variability) in the HPV16+ 
variants (Figure 18). IFN gamma was undetected in all samples, but due to reference 
gene variation, L83V is significantly lower than NIKS (P < 0.05). IFN kappa had very 
low biological variability in all samples and higher detectable expression (Ct = 35 to 36). 
IFN kappa expression is significantly decreased in L83V (~0.57 fold change) and AA 
(~0.17 fold change) compared to NIKS and prototype (P < 0.05). Additionally, IFN 
kappa in AA is significantly lower than L83V (P < 0.05). IFN lambda was near the limit 
of detection (Ct ~ 40), with no significant differences found. 
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Figure 18. Relative expression ratio of interferons. 
Fold difference, calculated by Livak method (2^delta delta Ct, NIKS as calibrator, 
HPRT1 as reference gene), square-root transformed to re-scale data. IFN beta expression 
is not significantly different (P = 0.17). IFN gamma expression is significantly lowered in 
L83V compared to NIKS and Proto (P < 0.05), but not AA (P = 0.57). L83V and AA 
have significantly down-regulated IFN kappa expression compared to NIKS and Proto (P 
< 0.05), while AA has significantly lower expression than L83V (P < 0.05). IFN lambda 
had no significant differences (P = 0.47). Data are means +/- SEM (n = 3): statistical 
analyses by ANOVA and TukeyHSD post-hoc. Asterisks represent significance. 
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3.5.2 Toll-Like Receptors 
 As seen with IFN expression analysis, TLR transcripts were also very low 
(Figure 19). TLR3 was the only assay that gave <35 Ct values (Ct = 28 to 30), while 
TLR4 and 9 have results between 35 and 40 Ct. TLR 7 and 8, however, are at the 
detection limit of 40 Ct and likely not valid for interpretation (any differences seen are 
mainly due to slight reference gene variation rather than actual transcript differences). 
Proto (~0.4 fold change), L83V (~0.2 fold change), and AA (~0.15 fold change) HPV16+ 
rafts all had significantly decreased TLR3 compared to untransfected NIKS (P < 0.001). 
Variant-specific TLR3 down-regulation was also observed, with L83V and AA having 
lower expression than Proto (P < 0.05). TLR4 expression was ~0.15 fold lower in L83V 
(P < 0.05) compared to NIKS. TLR7 expression was unchanged (P > 0.05). TLR8 
expression was lower in L83V (P < 0.05), but likely invalid due to detection limit. TLR9 
expression was ~2-3 fold higher in Proto and AA (P < 0.05) compared to NIKS. 
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Figure 19. Relative expression ratio of toll-like receptors. 
Fold difference, calculated by Livak method (2^delta delta Ct, NIKS as calibrator, 
HPRT1 as reference gene). TLR3 expression is lowered in Proto, AA, and L83V 
HPV16+ rafts (P < 0.001). AA and L83V TLR3 expression is less than Proto (P < 0.05). 
TLR4 expression is lower in L83V (P < 0.05). TLR7 expression was unchanged (P > 
0.05). TLR8 expression was lower in L83V (P < 0.05). TLR9 expression was higher in 
Proto and AA (P < 0.05). Data are presented as mean +/- SEM (n = 3): statistical analyses 
by ANOVA and TukeyHSD post-hoc tests. Asterisks represent significance. 
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4 DISCUSSION 
4.1 Establishment of HPV16 E6 Variant Cell Lines 
 The first step was to prepare the experimental groups using various molecular 
biology techniques such as transformation, restriction digest, ligation, and transfections. 
NIKS were chosen as host cells rather than primary human foreskin keratinocytes 
because of their ability to be grown indefinitely and undergo normal differentiation 
(Flores et al., 1999; Allen-Hoffman et al., 2000). NIKS transfected with full-length 
HPV16 E6 variant DNA were successfully obtained and verified via E6 DNA PCR 
(Figure 9). As discussed by Lambert et al. (2005), transfectants with episomal DNA 
required special care to prevent genomic integration of viral DNA. Additionally, all 
transfectants were prepared in the same way, limiting any differences due to technical 
variability between experiments. Another important factor to successful establishment of 
transfectants was ensuring Mycoplasma contamination was not present. Mycoplasma are 
a common cell-culture contaminant and cause low transfection efficiencies (Xia et al., 
1997) along with gene expression changes (Jung et al., 2003) in host cultures. Given the 
purpose of this study was to introduce viral DNA via transfection followed by gene 
expression analyses, a Mycoplasma infection would have been detrimental to validity. 
Routine testing for contamination was performed, allowing us to be confident that 
expression changes in our cultures were due to experimental conditions rather than an 
infection. 
56 
 
4.2 Development of Organotypic Model 
 Once HPV16 E6 variant cell lines were established it was necessary to employ an 
organotypic tissue culture model to enable an active viral life cycle (Lambert et al., 
2005). To accurately reproduce the skin, it's necessary to recreate the important layers: 
dermis and epidermis (Lambert et al., 2005). For recreating the dermis, collagen was 
embedded with fibroblasts and formed into solidified plugs. This structure provides a 
life-like structural support for keratinocytes to grow upon. Through many trials, it was 
determined that rat tail collagen, type I, at a concentration between 3.75 and 4.00 mg/mL, 
was ideal (Figure 11). Bovine collagen and lower concentrations (such as 2.00 mg/mL) 
were unsuccessful, yielding weak dermal equivalents. Early-passage human foreskin 
fibroblasts yielded the best epidermal growth. Given that non-immortal primary cultures 
senesce after fixed population doublings (Hayflick, 1965), it's reasonable to suggest that 
high-passage fibroblasts can result in poor raft growth. When creating the basal 
keratinocyte layer atop the dermis, it's essential to use media containing epidermal 
growth factor (EGF). EGF binds to EGF-receptor leading to activation of DNA 
transcription; proliferation of NIKS cells is severely inhibited by its absence and 
formation of a fully-packed basal layer is retarded (Allen-Hoffman et al., 2000). After the 
basal keratinocyte layer is established, differentiation can be induced by lifting the raft 
onto a membrane, forming an air-liquid interface (Poumay and Coquette, 2007). If not 
done carefully, lifting can disrupt or destroy raft cultures. Additionally, differentiation of 
NIKS requires media with the omission of EGF and supplementation with calcium 
(Lambert et al., 2005), fed through the bottom of each membrane in a 6 well-plate.  
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4.3 Phenotypic Characterization of Rafts 
 As verified by morphological assessment, raft cultures were successfully grown to 
mimic human skin (Figure 11). However, a common finding in all raft cultures was 
different epithelial thickness across the diameter of each circular raft. The outer edges of 
each raft were thicker than the middle, indicating uneven distribution of cells during 
establishment or a lack of nutrient medium being fed into the centre. Given that the rafts 
were atop a membrane in a 6-well plate, it was easy to ensure the entire bottom of the raft 
was interfaced with medium. When keratinocytes were added they were confirmed via 
microscopy to be homogenously distributed. The likely culprit is collagen contraction 
within 24-well plates after seeding keratinocytes, causing the cells to be distally clumped 
(Lambert at al., 2005). Although the lack of a full-thickness epithelium throughout an 
entire raft is disconcerting from a morphological perspective, it doesn't preclude 
verification of an active viral life cycle (the ultimate test). However, to determine if a 
better raft model was possible an alternative approach was attempted (Appendix 7.1).  
 An inferential study on innate immune evasion in an early-infection scenario 
requires the confirmation of an active viral life cycle: one that is capable of manipulating 
keratinocyte differentiation and producing virus. The best direct evidence for this would 
be visual confirmation of viral particles using a transmission electron microscope. 
Unfortunately, this method requires an ultramicrotome to cut extremely thin tissue 
sections, a service not available to me. Viral life cycle was instead confirmed using 
standardized immunohistochemistry for a set of specific markers: HPV16 L2 indicating 
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end-stage production of virus, BrdU incorporation for cell proliferation (Flores et al., 
1999), and keratins 5 and 10 for differentiation pattern (Zehbe et al., 2009). 
  Presence of HPV16 minor capsid protein L2 in the upper layers of epithelium, as 
supported by previous literature, is strong evidence of an active viral life cycle (Doorbar, 
2005). L2 along with L1 are produced during late-stage expression to encapsidate the 
supply of viral genomes before complete particles are released into the environment. 
Interestingly, the AA variant having the lowest detectable L2 (Figure 12) indicates that 
AA may have a temporally longer or shorter viral life cycle, along with reduced 
productive output. Suprabasal incorporation of BrdU into DNA indicates basal 
keratinocytes that are continuing to proliferate rather than terminally differentiating. 
HPV16 variants increased suprabasal incorporation compared to NIKS (Figure 13), 
indicating an active effect of early gene expression by E6 and E7 (Flores et al., 1999). 
Another interesting finding is that nearly every suprabasal cell of AA is actively 
undergoing DNA synthesis. Taken with the observation that L2 staining is minimal, this 
points toward a longer viral life cycle in AA. Additionally, keratin dysregulation in AA 
reveals that basal keratinocyte marker K5 is present in the suprabasal proliferating cells 
(Figure 14). Most evident in prototype, there are disruptions to differentiation marker 
K10, indicating a mixing of regular cell compartments. Although to a greater extent, 
similar differentiation patterns caused by HPV16 E6 variants have been observed in 
retrovirally transduced NIKS (Zehbe et al., 2009). Overall, phenotypic characterization of 
the organotypic cultures reveals that this was an appropriate model for study. 
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4.4 Viral Gene Expression 
 With HPV16 E6 variant-transduced keratinocytes successfully grown using a 
verified model system, the next logical step was molecular analyses. Changes in 
messenger RNA (mRNA) expression are a useful measure of the molecular environment 
within cells (Crick, 1970). Although mRNA transcript expression detected using RT-
qPCR may not unerringly equate to the amount of that protein, it's a valuable method to 
quantify activation of genes. The primary disadvantage of standard RT-qPCR without 
pre-amplification is the difficulty of detecting low-copy number transcripts due to 
detection limits (DeCarlo et al., 2010). The reliability of data (cycle thresholds) 
diminishes as the detection limit is approached (Ct = 40). A threshold is typically set as 
an arbitrary cut-off for reliable data (Bustin et al., 2009). Finally, the analysis of Ct 
values typically requires normalization to a reference gene and control sample; for this 
study, relative expression was calculated based on the Livak method, since Ct values are 
exponential in nature (Livak and Schmittgen, 2001). 
 To understand the state of viral gene expression, early oncogenes E6 and E7 were 
measured, as well as viral life cycle marker E1^E4. Variant-specific expression 
differences were not found, likely due to a lack of statistical power (Figures 15, 16, 17). 
Sample variances were heterogeneous and not amenable to more powerful parametric 
analysis. Additionally, the small sample size coupled with small effect size do not allow 
detectable differences to be found. Although not significant, an increase in E6 and E7 
expression in AA indicates early expression differences, and a likely delay of the viral 
life cycle. This fits with the low detection of E1^E4 (Figure 17), which is expressed 
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during the productive stage of the viral life cycle (Bodily et al., 2011). Protein-level 
detection by western blot or immunohistochemistry can be used in the future to discern if 
there are actually any differences between variants. 
4.5 Innate Immune System Gene Expression  
 As hypothesized, we found variant-specific differences in the host keratinocyte 
innate immune system activation and response. As described in the previous section, 
transcripts at low level pose a problem for analysis and interpretation. Innate immune 
system genes, such as some interferons and toll-like receptors, are known to be expressed 
at low levels (DeCarlo et al., 2010; DeCarlo et al., 2012). With the exception of IFN-κ 
and TLR3, most innate immunity genes analyzed are near the detection limit (Ct = 35 to 
40, possibly not reliable, and do not offer valid interpretation (Figures 18, 19). Further 
experiments with a pre-amplification step, as described by DeCarlo et al., 2010, are 
required to raise the relative transcript-levels to a reliably detectable range. 
 IFNs and TLRs are typically activated by viral infection; dengue virus replication 
elicits an antiviral innate immune response in infected human keratinocytes 
(Surasombatpattana et al., 2011). Specifically, TLR3 is cyclically expressed as a trans-
endosomal membrane receptor that responds to dsRNA, a product of most viral life 
cycles (Jorgenson et al., 2005). TLR3, which can be induced by IFN expression, leads to 
immune response factor activation, causing transcription of TNF, COX2, and IL-18 
(Khoo et al., 2011). In response to most viral infections, the typical response is an 
activation of IFNs and TLR3. However, our results suggest that an active HPV16 viral 
life cycle, specifically of the L83V and AA variant, evades the host innate immune 
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response by down-regulating IFN-κ and TLR3 (Figures 18, 19). As reported by Reiser at 
al. (2011), high-risk HPVs, such as type 16, repress constitutive IFN-κ transcription via 
E6, preventing induction of pathogen recognition receptors such as TLR3 and other 
antiviral genes. Studies of mucosal swab samples build upon this evidence, showing that 
in cases of persistent infections TLR3 expression was dampened (Daud et al., 2011). 
Recent studies of IFN, TLR, and integrin expression using ex vivo samples has revealed 
the unique immune responses in the microenvironment of normal, dysplastic, and 
carcinoma tissues (DeCarlo et al., 2008; DeCarlo et al., 2010; DeCarlo et al., 2011; 
Werner et al., 2012). The results reported here fill an important void, in that we have now 
characterized the effects of an early-infection on innate immunity in the context of the 
variants. Our results, taken together with the epidemiological evidence of variant-specific 
prevalences in cervical cancer (Zehbe et al., 1998), and the growing evidence offered by 
transformation studies (Niccoli et al., 2012), suggest that immune evasion by AA and 
L83V may lead to a state of persistent infection, with increased transformation potential, 
and higher prevalence in invasive cervical cancer. 
 
5 CONCLUSIONS AND FUTURE DIRECTIONS 
 Overall, an organotypic tissue culture model for HPV-infected skin was 
successfully established. Phenotypic characterization verified the experimental model, 
while molecular analyses yielded evidence for significant variant-specific decrease of 
antiviral innate immune responses in host keratinocytes. Asian-American and L83V 
HPV16 E6 variants appear to have increased host immune evasion capabilities over the 
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Prototype. Interestingly, productive viral life cycle was lowest in the AA variant: an 
unexpected result. Further experimentation is required to determine if there are temporal 
differences between the viral life cycles of the variants. Additionally, pre-amplification is 
required to reliably detect low-level transcripts. These future experiments will determine 
if the differential gene expression patterns are reproducible and if the viral life cycle 
occurs earlier or later in AA. A delayed viral life cycle in AA could have implications for 
its immune evasion capabilities. 
 Since these experiments yield variant-specific effects within the host 
transcriptome a future direction is to employ high-throughput analysis such as Affymetrix 
microarray or RNA-sequencing followed by bioinformatics analyses. Such a study will 
yield a global transcript expression profile. HPV16 E6 variant profiles can be compared 
to HPV-negative NIKS profiles to construct an infectome map of all host gene expression 
changes in response to an active viral life cycle. In addition to bioinformatics analyses, 
protein-level detection of E6 can be used to monitor functional effects on host proteins 
(Jackson and Zehbe, 2012). Finally, the major limitation of the organotypic tissue culture 
model is the lack of a circulatory and an adaptive immune system. These in vitro 
limitations could be ameliorated by using an appropriate in vivo mouse model.  
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7 APPENDIX 
7.1 Alternative Organotypic Culture Model 
 As an additional validation of the organotypic model culture, an alternative  
culture system was morphologically assessed. Given that the main drawback of our 
default culturing system was variable epithelial thickness and differentiation between 
distal and medial areas, the use of a scaffold was justified. Alvetex® 6-well polystyrene 
scaffold inserts (Reinnervate, Cat. No. AVP004-3) were prepared and grown with NIKS 
cells according to supplier protocols employing collagen coating. Routine culturing of 
Alvetex® scaffolds was troublesome due to the increased volume of media required and 
porosity of the membrane. The scaffolds are raised and require 5x more medium than 
other rafts. Additionally, collagen and cells seeded on top of the scaffold leaked through 
the membrane, contaminating the 6-well plates. Plates had to be changed frequently to 
prevent media sequestering by these cells. Finally, the membrane needs to be cut from the 
plastic supports, increasing the amount of manipulation while harvesting. Morphological 
assessment of NIKS grown on an Alvetex® scaffold show poor epithelial differentiation 
across the entire layer and a disrupted dermis (Figure 20). Fibroblasts and collagen 
appear to have leaked through and settled to the bottom of the scaffold. 
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Figure 20. NIKS culture morphology with Alvetex® scaffold. 
Haematoxylin and eosin stain (200X magnification) of cross-sectioned formalin-fixed 
paraffin-embedded NIKS organotypic culture grown for 2 weeks using an Alvetex® 
scaffold. The epidermis, dermis, and scaffold layers are labelled. 
 
 
73 
 
 Overall, our organotypic culture model performed better than Alvetex® scaffolds 
in terms of simplicity, cost effectiveness, and morphology. However, using a classical 
culture format with a dermal equivalent (collagen with embedded fibroblasts) does not 
seem appropriate for these scaffolds. Rather than mimicking the dermis atop, it may be 
possible to grow fibroblasts directly within the scaffold without an exogenous collagen 
matrix.  
